Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Cantor Fitzgerald
Fuji
Chubb
Mallinckrodt
Boehringer Ingelheim
Federal Trade Commission
Baxter
Accenture

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AMYVID

« Back to Dashboard

Clinical Trials for Amyvid

Trial ID Title Status Sponsor Phase Summary
NCT00702143 A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) Completed Avid Radiopharmaceuticals Phase 2 Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
NCT00857415 Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain Completed Avid Radiopharmaceuticals Phase 3 The study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid by dissection of the brain at autopsy. Amyloid in the brain is a key feature of Alzheimer's Disease (AD).
NCT00857532 Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 2 The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.
NCT00857532 Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients Completed National Institutes of Health (NIH) Phase 2 The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.
NCT00857532 Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients Completed Avid Radiopharmaceuticals Phase 2 The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.
NCT01400425 Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline Completed Avid Radiopharmaceuticals Phase 3 The study is designed to evaluate whether a florbetapir F 18 PET scan can impact clinical thinking when physicians are determining the likely cause of a subject's cognitive impairment.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Amyvid

Condition Name

Condition Name for Amyvid
Intervention Trials
Alzheimer's Disease 16
Alzheimer Disease 5
Mild Cognitive Impairment 5
Chronic Traumatic Encephalopathy 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Amyvid
Intervention Trials
Alzheimer Disease 24
Cognition Disorders 7
Dementia 5
Mild Cognitive Impairment 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Amyvid

Trials by Country

Trials by Country for Amyvid
Location Trials
United States 123
Canada 6
Italy 5
Australia 5
Spain 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Amyvid
Location Trials
Florida 11
Pennsylvania 10
California 10
Connecticut 8
Arizona 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Amyvid

Clinical Trial Phase

Clinical Trial Phase for Amyvid
Clinical Trial Phase Trials
Phase 4 6
Phase 3 3
Phase 2/Phase 3 2
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Amyvid
Clinical Trial Phase Trials
Completed 20
Recruiting 5
Active, not recruiting 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Amyvid

Sponsor Name

Sponsor Name for Amyvid
Sponsor Trials
Avid Radiopharmaceuticals 24
Eli Lilly and Company 4
Molecular NeuroImaging 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Amyvid
Sponsor Trials
Industry 33
Other 9
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Cantor Fitzgerald
Baxter
Boehringer Ingelheim
Daiichi Sankyo
Healthtrust
Dow
QuintilesIMS
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.